A Pilot Study of Adherence to Oral Anticancer Treatment Using Electronic Monitoring System
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 33
- 试验地点
- 2
- 主要终点
- evaluation of adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor.
研究概览
简要总结
The purpose of this study is to describe adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor. Moreover, this study is aimed at evaluating the feasibility to use a " Medication Event Monitoring System " (MEMS®) in order to assess adherence of an oral anticancer treatment delivered by dispensary pharmacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years
- •histologically proven malignant tumor
- •documented decision of treatment with i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor
- •ambulatory treated subject
- •Subject who accept to use MEMS monitors to automatically compile their drug dosing histories
- •Written informed consent
排除标准
- •any severe concomitant wich makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol
- •patient who does not agreed to participate the program
结局指标
主要结局
evaluation of adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor.
时间窗: everey visit during 6 months
次要结局
- evaluation of liberal nurse satisfaction(inclusion)
- resort to healthcare system (oncologist, doctor, nurse, hospital pharmacy, dispensary pharmacy)(during 6 months)
- Patient satisfaction(6 months)
- drug interaction(during 6 months)
